The GenoType ® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden

APMIS

Volumn 120, Issue 5, 2012, Pages 405-409

  Chryssanthou, Erja ^a   Ängeby, Kristian ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Isoniazid; Line probe assay; Multidrug resistance; Mycobacterium tuberculosis; Rifampicin

Indexed keywords

BACTERIAL PROTEIN; INHA PROTEIN; ISONIAZID; KATG PROTEIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BIOASSAY; CODON; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; WILD TYPE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SWEDEN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84860011926     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02845.x     Document Type: Article

References (9)

1. Drobniewski F, Rüsch-Gerdes S, Hoffner S. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E. DEF 8.1) report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007;13:1144-56.
2. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007;45:2635-40.
3. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010;10:149.
4. Almeida Da Silva PA, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011;66:1417-30.
5. Hazbón MH, Brimacombe M, Bodadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population Genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006;50:2640-9.
6. Leung ET, Ho PL, Yuen KY, Woo WL, Lam TH, Kao RY, et al. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob Agents Chemother 2006;50:1075-8.
7. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis 2010;10:123.
8. Schaaf HS, Victor TC, Venter A, Brittle W, Jordaan AM, Hesseling AC, et al. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13:1355-9.
9. Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 2006;44:2333-7.